Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Icu Medical (ICUI) Research & Development (2016 - 2025)

Icu Medical's Research & Development history spans 17 years, with the latest figure at $21.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 5.68% year-over-year to $21.1 million, compared with a TTM value of $87.5 million through Dec 2025, down 1.26%, and an annual FY2025 reading of $87.5 million, down 1.26% over the prior year.
  • Research & Development for Q4 2025 was $21.1 million at Icu Medical, down from $21.3 million in the prior quarter.
  • The five-year high for Research & Development was $23.9 million in Q1 2022, with the low at $10.7 million in Q1 2021.
  • Average Research & Development over 5 years is $20.1 million, with a median of $21.9 million recorded in 2024.
  • Year-over-year, Research & Development soared 122.91% in 2022 and then fell 17.22% in 2023.
  • Tracing ICUI's Research & Development over 5 years: stood at $13.2 million in 2021, then surged by 78.08% to $23.4 million in 2022, then fell by 4.41% to $22.4 million in 2023, then fell by 0.25% to $22.4 million in 2024, then fell by 5.68% to $21.1 million in 2025.
  • Per Business Quant, the three most recent readings for ICUI's Research & Development are $21.1 million (Q4 2025), $21.3 million (Q3 2025), and $21.9 million (Q2 2025).